Show simple item record

dc.contributor.authorJia, Bin
dc.contributor.authorNg, Sharon K
dc.contributor.authorDeGottardi, M. Quinn
dc.contributor.authorPiatak, Michael
dc.contributor.authorYuste, Eloisa
dc.contributor.authorCarville, Angela
dc.contributor.authorMansfield, Keith G.
dc.contributor.authorLi, Wenjun
dc.contributor.authorRichardson, Barbra A.
dc.contributor.authorLifson, Jeffrey D.
dc.contributor.authorEvans, David T.
dc.date2022-08-11T08:10:21.000
dc.date.accessioned2022-08-23T17:05:30Z
dc.date.available2022-08-23T17:05:30Z
dc.date.issued2009-01-23
dc.date.submitted2014-06-03
dc.identifier.citationJia B, Ng SK, DeGottardi MQ, Piatak M Jr, Yuste E, et al. (2009) Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIVmac239. PLoS Pathog 5(1): e1000272. doi:10.1371/journal.ppat.1000272 <a href="http://dx.doi.org/10.1371/journal.ppat.1000272">Link to article on publisher's site</a>
dc.identifier.issn1553-7366 (Linking)
dc.identifier.doi10.1371/journal.ppat.1000272
dc.identifier.pmid19165322
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44870
dc.description.abstractStrains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4(+) T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIV(mac)239. However, significantly lower viral loads and higher memory CD4(+) T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIV(mac)239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19165322&dopt=Abstract">Link to Article in PubMed</a>
dc.rights<p>Copyright 2009 Jia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
dc.subjectAnimals
dc.subjectAntibodies, Viral
dc.subjectCD4-Positive T-Lymphocytes
dc.subjectCD8-Positive T-Lymphocytes
dc.subjectImmunization
dc.subjectMacaca mulatta
dc.subjectRNA, Viral
dc.subjectSimian Acquired Immunodeficiency Syndrome
dc.subjectSimian immunodeficiency virus
dc.subjectVesiculovirus
dc.subjectViral Load
dc.subjectAntibodies
dc.subjectEnzyme-linked immunoassays
dc.subjectImmune response
dc.subjectMemory T cells
dc.subjectSIV
dc.subjectT cells
dc.subjectViral load
dc.subjectViral replication
dc.subjectImmunology and Infectious Disease
dc.subjectImmunopathology
dc.titleImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239
dc.typeJournal Article
dc.source.journaltitlePLoS pathogens
dc.source.volume5
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1291&amp;context=prevbeh_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/prevbeh_pp/292
dc.identifier.contextkey5647120
refterms.dateFOA2022-08-23T17:05:30Z
html.description.abstract<p>Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIV(mac)239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4(+) T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIV(mac)239. However, significantly lower viral loads and higher memory CD4(+) T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIV(mac)239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV.</p>
dc.identifier.submissionpathprevbeh_pp/292
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavioral Medicine
dc.source.pagese1000272


Files in this item

Thumbnail
Name:
Li_Immunization_journal.ppat.1 ...
Size:
2.443Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record